Prof. Itamar Raz, Director of the Diabetes Unit at the Hadassah Medical Center in Jerusalem, will co-chair the large international research trial, SAVOR (Saxagliptin in Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus.) The trial will assess the effects of Saxagliptin,( Onglyza™ - a novel DPP4 inhibitor medication which enhances response to incretin, a hormone that works to increase insulin activity) on cardiovascular events in type 2 diabetic patients. Prof. Raz will co-chair the study in collaboration with Dr. Eugene Braunwald, Chairman of the TIMI (Thrombolysis in Myocardial Infarction) Study Group of Boston, USA, a world leader in conducting clinical trials that assess the care of patients with coronary artery diseases. The SAVOR study is sponsored by the Bristol-Myers Squibb/AstraZeneca Diabetes Collaboration, which is dedicated to global patient care, improving patient outcomes and creating a new vision for the treatment of type 2 diabetes..
SAVOR- TIMI 53 will be conducted over five years in multiple countries world wide– including Israel – with targeted enrollment of 12,000 patients with type 2 diabetes. Onglyza™ is currently approved in 40 countries, including the United States and the European Union, and was recently submitted for registration in Israel.
Two principal investigators – an endocrinologist and a cardiologist – were selected to lead the project in each participating country. In addition to co-chairing the international effort, Prof. Raz will lead the Israeli research team in conjunction with Prof. Basil Lewis of the Carmel Medical Center in Haifa.
An international scientific committee will supervise the execution of the project and convene every few months to analyze the data and provide recommendations on the direction of the research. Prof. Raz and Prof. Eran Leitersdorf, Dean of Hebrew University-Hadassah School of Medicine, are members of this committee.
"This study is aimed at assessing whether a new medication, from the family of incretin medications, has any impact on the risk of cardiovascular events and their related mortality in patients with type 2 diabetes," Prof. Itamar Raz said. "It is an honor to collaborate with Dr. Braunwald and the TIMI Group and I look forward to working with them”.